BLUE:NSD-bluebird bio Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 20.90

Change

0.00 (0.00)%

Market Cap

USD 1.41B

Volume

2.04M

Avg Analyst Target

USD 26.00 (+24.40%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases and cancer. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; LentiGlobin for the treatment of sickle cell disease; and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. The company's product candidates in oncology include Idecabtagene vicleucel and bb21217, which are chimeric antigen receptor T (CAR T) cell product candidates for the treatment of multiple myeloma. It has collaboration and license agreements with Bristol-Myers Squibb, Regeneron Pharmaceuticals, Inc., Novartis Pharma AG, Orchard Therapeutics Limited, Medigene AG, Novo Nordisk A/S, Forty Seven, Inc., Gritstone Oncology, Inc., Magenta Therapeutics, Inc., the Seattle Children's Research Institute, University of North Carolina, and the Fred Hutchinson Cancer Research Center. bluebird bio, Inc. has a strategic alliance with National Resilience, Inc. to research, development, and delivery of cell therapies. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Cambridge, Massachusetts. Address: 60 Binney Street, Cambridge, MA, United States, 02142

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-10-17 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna Inc

N/A

USD130.87B 38.30 29.43
BNTX BioNTech SE

N/A

USD60.07B 13.83 10.18
REGN Regeneron Pharmaceuticals Inc

N/A

USD59.17B 9.99 7.57
VRTX Vertex Pharmaceuticals Incorpo..

N/A

USD47.16B 23.96 15.75
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
BGNE BeiGene Ltd

N/A

USD33.45B N/A N/A
SGEN Seagen Inc

N/A

USD31.43B 53.89 40.74
GMAB Genmab A/S

N/A

USD29.05B 74.91 8.12
ALNY Alnylam Pharmaceuticals Inc

N/A

USD24.79B N/A N/A
RPRX Royalty Pharma plc

N/A

USD23.31B 31.09 11.82

ETFs Containing BLUE

Symbol Name Weight Mer Price(Change) Market Cap
LABD Direxion Daily S&P Biotec.. 0.00 % 1.07 %

N/A

USD0.06B
LABU Direxion Shares ETF Trust.. 0.00 % 1.02 %

N/A

USD0.77B
XBI SPDR S&P Biotech ETF 0.00 % 0.35 %

N/A

USD7.36B
ISMD Northern Lights Fund Trus.. 0.00 % 0.60 %

N/A

USD0.12B
DRUP:XETRA Lyxor Index Fund - Lyxor .. 0.00 % 0.45 %

N/A

USD0.34B
BBIG:CA Horizons Global BBIG Tech.. 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -51.70% 13% F 7% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -51.70% 13% F 7% F
Trailing 12 Months  
Capital Gain -62.75% 8% F 3% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -62.75% 8% F 3% F
Trailing 5 Years  
Capital Gain -61.93% 33% F 11% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -61.93% 33% F 10% F
Average Annual (5 Year Horizon)  
Capital Gain -3.02% 29% F 15% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -3.02% 29% F 14% F
Risk Return Profile  
Volatility (Standard Deviation) 72.93% 42% F 24% F
Risk Adjusted Return -4.14% 30% F 18% F
Market Capitalization 1.41B 79% C+ 70% C-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 1.37 87% B+ 74% C
Price / Cash Flow Ratio -3.00 25% F 60% D-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -63.16% 44% F 24% F
Return on Invested Capital -47.74% 51% F 17% F
Return on Assets -30.07% 39% F 11% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 5.51 41% F 26% F
Short Percent 8.65% 28% F 20% F
Beta 1.57 36% F 25% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

Discussions

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.